EGRX News and Press, Eagle Pharmaceuticals Inc. From 12/22/23

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 investing in Eagle Pharmaceuticals stock or options between August 8,...

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 investing in Eagle Pharmaceuticals stock or options between August 8,...

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 investing in Eagle Pharmaceuticals stock or options between August 8,...

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages EGRX Investors with Substantial Losses to Contact Firm San Francisco, California--(Newsfile Corp. - December 12, 2023) - Hagens Berman urges Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) investors who suffered substantial losses to submit your ...

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Eagle Pharmaceuticals To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Eagle Pharmaceuticals and would like to discuss your legal rights, call Fa...

-- BARHEMSYS ® (amisulpride) Injection is the first and only antiemetic approved by the U.S. Food and Drug Administration (“FDA”) for rescue treatment of postoperative nausea and vomiting (“PONV”) despite prophylaxis 1 and is also approved for the treatmen...

2023-12-04 15:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-01 15:00:02 ET More on the markets My Current View Of The S&P 500 Index: December 2023 Edition SPY: Powell's Friday Speech To Likely 'Kill' The Rally 2024 Outlook: Recession AND New All-Time Highs Bond proxies and quality stocks are expected to do...

Boston, Massachusetts--(Newsfile Corp. - December 1, 2023) - Block & Leviton is investigating Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) for potential securities law violations. Investors who have lost money in their Eagle Pharmaceuticals, Inc. investment should contact the firm to learn mo...

The law firm of Kirby McInerney LLP is investigating potential claims against Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX ). The investigation concerns whether Eagle and/or certain of its officers have violated the federal securities la...